Obesity and antibiotics: study seeks safer dosing
NCT ID NCT06601257
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how to give the antibiotic vancomycin to obese adults. Researchers compared dosing based on weight versus kidney function to see which gives better drug levels. 35 healthy obese volunteers received a single dose and provided blood and urine samples. The goal is to improve safety and effectiveness of vancomycin in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vancomycin
- What this could lead to
- If successful, this could lead to better, safer dosing guidelines for vancomycin in people with obesity.
- What could go wrong
- This is a small, early-phase study with only 35 participants, so results may not apply to everyone. It focuses on drug levels, not direct treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS AND PHARMACODYNAMICS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Michigan Clinical Research Unit
Ann Arbor, Michigan, 48108, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.